PACAP-27 CAS 127317-03-7

Neurohypophysin also has a certain impact on cardiovascular function. It can act on myocardial cells, affecting the contractility and heart rate of the myocardium. Although there is relatively little research in this area, some studies suggest that pituitary hormones may be associated with the occurrence and development of cardiovascular diseases.

In addition, pituitary hormones may also participate in angiogenesis and repair processes by affecting the function of endothelial cells. These effects are of great significance for maintaining the normal structure and function of the cardiovascular system.

In addition to the aforementioned functions, neurophysin also plays a certain role in the reproductive and lactation processes. In mammals, pituitary hormones can stimulate mammary epithelial cells to secrete milk, which is crucial for the growth and development of newborns. In addition, pituitary hormones may also participate in the regulation of the reproductive system, affecting the secretion of gonadotropins and the development of reproductive cells.

Due to its important role in physiological processes, neurohypophysin also has broad application value in the medical field. For example, in the treatment of diabetes insipidus, exogenous supplementation of neuropituitarin can be used to correct the patient's abnormal water metabolism; In anti shock therapy, neurophysin can increase hypertension, improve microcirculation, and help restore organ function.

PACAP-27 is a potent broad-spectrum neuroprotective factor that selectively counteracts various central nervous system injuries, applicable to two major research scenarios: acute neurological damage and chronic neurodegenerative disorders.

For acute injuries, in preclinical models of stroke, traumatic brain injury and spinal cord injury, ovine penetrates the compromised blood-brain barrier, inhibits glutamate excitotoxicity and massive accumulation of oxygen free radicals, and blocks neuronal apoptotic pathways.

Meanwhile, it alleviates cerebral edema by downregulating aquaporin expression, suppresses excessive microglial activation, and curbs neuroinflammatory cascades triggered by pro-inflammatory factors such as TNF-α and IL-6. It effectively reduces cerebral infarct volume and ameliorates motor and neurological deficits in animals. Compared with PACAP-38, ovine exhibits superior local penetration upon topical administration, rendering it the preferred peptide for research on acute central nervous system injury intervention.

In research on chronic neurodegenerative diseases, ovine exerts consistent neuronal reparative capacity. In Parkinson's disease models, it selectively protects dopaminergic neurons in the substantia nigra, reduces neuronal apoptosis, and alleviates motor dysfunction. In Alzheimer's disease studies, it inhibits toxic Aβ protein deposition and tau hyperphosphorylation, mitigating damage to hippocampal neurons. Furthermore, it suppresses multiple forms of programmed neuronal death including ferroptosis and pyroptosis, slowing neurodegenerative progression in amyotrophic lateral sclerosis, multiple sclerosis and other conditions. It serves as a vital research tool for mechanistic investigation and drug screening of degenerative encephalopathies.

Neural plasticity constitutes the core foundation of learning, memory and neurological functional recovery. Ovine is highly expressed in core cognitive brain regions including the hippocampus and cerebral cortex, and profoundly modulates synaptic plasticity via the PAC1R-cAMP-CREB signaling pathway. It facilitates neurite outgrowth, synaptic structural remodeling and myelin repair, markedly enhances hippocampal long-term potentiation, and facilitates memory consolidation and information storage, making it a key endogenous regulator of cognitive function.

Numerous studies have verified that ovine knockout leads to reduced synaptic density and impaired learning and memory in mice, while exogenous supplementation effectively alleviates cognitive decline induced by aging and brain injury.

Additionally, ovine participates in central circadian rhythm regulation with abundant expression in the suprachiasmatic nucleus.

It synchronizes systemic circadian rhythms and modulates sleep-wake cycles, opening new avenues for mechanistic research on sleep disorders accompanied by cognitive impairment. It also regulates central synaptic neurotransmitter release to balance excitatory and inhibitory signals in the brain, ameliorating synaptic dysfunction caused by vascular dementia, fragile X syndrome and other disorders. It provides support for mechanistic elucidation and therapeutic development for cognitive impairment diseases.

PACAP-27 is extensively involved in central stress regulation, emotional modulation and addictive behavior control, serving as a critical target for neuropsychiatric research. It mediates systemic stress responses primarily by modulating the function of the hypothalamic-pituitary-adrenal (HPA) axis. Clinical studies have found that cerebrospinal fluid ovine levels are strongly correlated with the severity of post-traumatic stress disorder and anxiety, marking it a potential biomarker for disease assessment. Exogenous ovine balances HPA axis hormone secretion and relieves emotional disturbance and neurological damage induced by chronic stress.

In substance addiction research, ovine exerts unique targeted regulatory effects. It acts specifically on the nucleus accumbens to suppress alcohol-seeking behaviors in a dose-dependent manner without interfering with normal taste intake, a function distinctly different from PACAP-38. This offers an innovative direction for mechanistic research and targeted intervention of alcohol use disorders.

Moreover, it inhibits central neurogenic inflammation and stabilizes emotion-related neural circuits, holding important research value for chronic neuropathic pain and migraine complicated with mood disorders. To date, research on ovine has spanned multiple fields including stress disorders, addiction and mood disorders, laying a solid foundation for elucidating pathological mechanisms and developing novel therapeutic targets for psychiatric illnesses.

PACAP-27 is primarily known for its ability to activate adenylate cyclase, leading to an increase in cyclic adenosine monophosphate (cAMP) production. This, in turn, triggers a cascade of signaling events that can influence various cellular functions. While the direct impact of PACAP27 on water balance regulation has not been extensively studied, its effects on related physiological systems can provide insights into its potential role.

One way PACAP27 may indirectly influence water balance is through its effects on the cardiovascular system. PACAP27 has been shown to inhibit the secretion of atrial natriuretic peptide (ANP) from atrial myocytes. ANP is a hormone that plays a crucial role in sodium and water excretion, thereby affecting blood pressure and fluid balance. By inhibiting ANP secretion, PACAP27 may potentially alter the renal handling of sodium and water, although this link has not been directly established in the context of water balance regulation.

Furthermore, PACAP27's effects on the central nervous system (CNS) and neuroendocrine regulation may also have implications for water balance. The CNS integrates various sensory inputs related to hydration status and regulates fluid intake and excretion through neuroendocrine pathways. While direct evidence linking PACAP27 to these neuroendocrine mechanisms is lacking, its role in modulating neuronal activity and neurotransmitter release suggests that it could potentially influence water balance regulation at a higher level of organization.

It's worth noting that the majority of research on PACAP27 has focused on its effects in the context of other physiological systems, such as the cardiovascular, neuroendocrine, and immune systems. Therefore, the direct and specific role of PACAP27 in adjusting water balance remains an area of ongoing research and investigation.

In vitro studies

PACAP(1-27) effectively inhibits the increase in total pulmonary resistance induced by allergens or histamine in guinea pigs. Its bronchodilatory effects are comparable to those of salbutamol, but with a more favorable cardiovascular profile, as it does not significantly increase heart rate. These findings suggest that PACAP(1-27) may have therapeutic potential in the treatment of respiratory diseases, particularly in patients who are sensitive to the side effects of current bronchodilators.